$MAZE

Courtney Phillips sold $105K of MAZE

Courtney Phillips (GC and Corp. Secretary) sold 3,993 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.78–$27.12, $0.10M total) across 4 trades over 2026-09-02 to 2026-09-03.

Original reporting
SEC EDGAR · Courtney Phillips
Published Sep 4, 2026, 8:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MAZE
Neutral
medium confidence
Mentioned
$MAZE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAZENeutralLow
01

Why it matters

The sale represents a modest reduction in insider ownership, unlikely to affect investor sentiment significantly.

02

Market read

Small insider sell; limited trading relevance.

03

What to watch

No 10b5‑1 plan and the insider remains a significant holder (7,007 shares).

Relevance 4/10Novelty 6/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$MAZENeutralMedium confidence
Context

SEC Form 4 disclosed insider Courtney Phillips sold ~ $105K of Maze Therapeutics shares.

Expected impact

Limited downside pressure, likely negligible price change.

Evidence & confidence

Sale size is small relative to market cap and no 10b5-1 plan; typical insider sells have limited impact.

Market effects

None; transaction is company‑specific.

None; limited to U.S. biotech sector.

Minimal.

Counterpoint

Insider may be reallocating capital; could be a neutral or even positive signal if cash is used for growth.

Key entities

  • Courtney Phillips

    General Counsel and Corporate Secretary of Maze Therapeutics.

  • Maze Therapeutics, Inc.

    Biotech firm developing precision medicines for rare diseases.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MAZEMed

Maze Therapeutics, Inc. (MAZE): Results of Operations and Financial Condition

Maze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongo